LeHavreV1, PubMed, Corpus, bibRecord, 000240

MRI gadolinium-based contrast agents. Radiologists beware!

Identifieur interne : 000240 ( PubMed/Corpus ); précédent : 000239; suivant : 000241

MRI gadolinium-based contrast agents. Radiologists beware!

Auteurs : J-P Goullé ; A. Cattanéo ; E. Saussereau ; L. Mahieu ; M. Guerbet ; C. Lacroix

Source :

Annales pharmaceutiques francaises [ 0003-4509 ] ; 2009.

RBID : pubmed:19695369

English descriptors

KwdEn :
- Chelating Agents, Contrast Media (adverse effects), Fibrosis, France (epidemiology), Gadolinium (adverse effects), Gadolinium (pharmacokinetics), Humans, Kidney Diseases (chemically induced), Kidney Diseases (epidemiology), Kidney Diseases (pathology), Magnetic Resonance Imaging (adverse effects).
MESH :
- chemical , adverse effects : Contrast Media, Gadolinium.
- chemical , pharmacokinetics : Gadolinium.
- chemical : Chelating Agents.
- geographic , epidemiology : France.
- adverse effects : Magnetic Resonance Imaging.
- chemically induced : Kidney Diseases.
- epidemiology : Kidney Diseases.
- pathology : Kidney Diseases.
- Fibrosis, Humans.

Abstract

Gadolinium (Gd) is used in contrast agents as it enhances magnetic resonance imaging (MRI) signals. To reduce Gd toxicity, it is chelated into linear or macrocyclic complexes. Eight Gd-containing contrast agents have been approved by the European Medicines Agency (EMEA) for use in MRI, and six by the US Food and Drug Administration. Stability depends upon its physicochemical properties. When renal function is normal, the Gd is quickly cleared from the body by the kidneys. For patients with chronic kidney disease, the elimination is greatly reduced and Gd may be released from its chelate and deposit in body tissues, leading to nephrogenic systemic fibrosis (NSF). More than 200 cases of NSF have been reported in the world. NSF is characterized by an extensive fibrosis of skin and tissues, a very severe affection with possible lethal outcome. We propose recommendations to avoid the risk of NSF.

DOI: 10.1016/j.pharma.2009.06.002
PubMed: 19695369

Links to Exploration step

pubmed:19695369

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">MRI gadolinium-based contrast agents. Radiologists beware!</title>
<author><name sortKey="Goulle, J P" sort="Goulle, J P" uniqKey="Goulle J" first="J-P" last="Goullé">J-P Goullé</name>
<affiliation><nlm:affiliation>Laboratoire de pharmacocinétique et de toxicologie cliniques, groupe hospitalier du Havre, BP 24, 76083 Le Havre cedex, France. jean-pierre.goulle@ch-havre.fr</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Cattaneo, A" sort="Cattaneo, A" uniqKey="Cattaneo A" first="A" last="Cattanéo">A. Cattanéo</name>
</author>
<author><name sortKey="Saussereau, E" sort="Saussereau, E" uniqKey="Saussereau E" first="E" last="Saussereau">E. Saussereau</name>
</author>
<author><name sortKey="Mahieu, L" sort="Mahieu, L" uniqKey="Mahieu L" first="L" last="Mahieu">L. Mahieu</name>
</author>
<author><name sortKey="Guerbet, M" sort="Guerbet, M" uniqKey="Guerbet M" first="M" last="Guerbet">M. Guerbet</name>
</author>
<author><name sortKey="Lacroix, C" sort="Lacroix, C" uniqKey="Lacroix C" first="C" last="Lacroix">C. Lacroix</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2009">2009</date>
<idno type="RBID">pubmed:19695369</idno>
<idno type="pmid">19695369</idno>
<idno type="doi">10.1016/j.pharma.2009.06.002</idno>
<idno type="wicri:Area/PubMed/Corpus">000240</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">MRI gadolinium-based contrast agents. Radiologists beware!</title>
<author><name sortKey="Goulle, J P" sort="Goulle, J P" uniqKey="Goulle J" first="J-P" last="Goullé">J-P Goullé</name>
<affiliation><nlm:affiliation>Laboratoire de pharmacocinétique et de toxicologie cliniques, groupe hospitalier du Havre, BP 24, 76083 Le Havre cedex, France. jean-pierre.goulle@ch-havre.fr</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Cattaneo, A" sort="Cattaneo, A" uniqKey="Cattaneo A" first="A" last="Cattanéo">A. Cattanéo</name>
</author>
<author><name sortKey="Saussereau, E" sort="Saussereau, E" uniqKey="Saussereau E" first="E" last="Saussereau">E. Saussereau</name>
</author>
<author><name sortKey="Mahieu, L" sort="Mahieu, L" uniqKey="Mahieu L" first="L" last="Mahieu">L. Mahieu</name>
</author>
<author><name sortKey="Guerbet, M" sort="Guerbet, M" uniqKey="Guerbet M" first="M" last="Guerbet">M. Guerbet</name>
</author>
<author><name sortKey="Lacroix, C" sort="Lacroix, C" uniqKey="Lacroix C" first="C" last="Lacroix">C. Lacroix</name>
</author>
</analytic>
<series><title level="j">Annales pharmaceutiques francaises</title>
<idno type="ISSN">0003-4509</idno>
<imprint><date when="2009" type="published">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chelating Agents</term>
<term>Contrast Media (adverse effects)</term>
<term>Fibrosis</term>
<term>France (epidemiology)</term>
<term>Gadolinium (adverse effects)</term>
<term>Gadolinium (pharmacokinetics)</term>
<term>Humans</term>
<term>Kidney Diseases (chemically induced)</term>
<term>Kidney Diseases (epidemiology)</term>
<term>Kidney Diseases (pathology)</term>
<term>Magnetic Resonance Imaging (adverse effects)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Contrast Media</term>
<term>Gadolinium</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Gadolinium</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Chelating Agents</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>France</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Magnetic Resonance Imaging</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Kidney Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Kidney Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Kidney Diseases</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Fibrosis</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Gadolinium (Gd) is used in contrast agents as it enhances magnetic resonance imaging (MRI) signals. To reduce Gd toxicity, it is chelated into linear or macrocyclic complexes. Eight Gd-containing contrast agents have been approved by the European Medicines Agency (EMEA) for use in MRI, and six by the US Food and Drug Administration. Stability depends upon its physicochemical properties. When renal function is normal, the Gd is quickly cleared from the body by the kidneys. For patients with chronic kidney disease, the elimination is greatly reduced and Gd may be released from its chelate and deposit in body tissues, leading to nephrogenic systemic fibrosis (NSF). More than 200 cases of NSF have been reported in the world. NSF is characterized by an extensive fibrosis of skin and tissues, a very severe affection with possible lethal outcome. We propose recommendations to avoid the risk of NSF.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19695369</PMID>
<DateCreated><Year>2009</Year>
<Month>8</Month>
<Day>21</Day>
</DateCreated>
<DateCompleted><Year>2009</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>11</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0003-4509</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>67</Volume>
<Issue>5</Issue>
<PubDate><Year>2009</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Annales pharmaceutiques francaises</Title>
<ISOAbbreviation>Ann Pharm Fr</ISOAbbreviation>
</Journal>
<ArticleTitle>MRI gadolinium-based contrast agents. Radiologists beware!</ArticleTitle>
<Pagination><MedlinePgn>335-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pharma.2009.06.002</ELocationID>
<Abstract><AbstractText>Gadolinium (Gd) is used in contrast agents as it enhances magnetic resonance imaging (MRI) signals. To reduce Gd toxicity, it is chelated into linear or macrocyclic complexes. Eight Gd-containing contrast agents have been approved by the European Medicines Agency (EMEA) for use in MRI, and six by the US Food and Drug Administration. Stability depends upon its physicochemical properties. When renal function is normal, the Gd is quickly cleared from the body by the kidneys. For patients with chronic kidney disease, the elimination is greatly reduced and Gd may be released from its chelate and deposit in body tissues, leading to nephrogenic systemic fibrosis (NSF). More than 200 cases of NSF have been reported in the world. NSF is characterized by an extensive fibrosis of skin and tissues, a very severe affection with possible lethal outcome. We propose recommendations to avoid the risk of NSF.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goullé</LastName>
<ForeName>J-P</ForeName>
<Initials>JP</Initials>
<AffiliationInfo><Affiliation>Laboratoire de pharmacocinétique et de toxicologie cliniques, groupe hospitalier du Havre, BP 24, 76083 Le Havre cedex, France. jean-pierre.goulle@ch-havre.fr</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cattanéo</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Saussereau</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y"><LastName>Mahieu</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Guerbet</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lacroix</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
</AuthorList>
<Language>ENG</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2009</Year>
<Month>Jul</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>France</Country>
<MedlineTA>Ann Pharm Fr</MedlineTA>
<NlmUniqueID>2985176R</NlmUniqueID>
<ISSNLinking>0003-4509</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002614">Chelating Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003287">Contrast Media</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>AU0V1LM3JT</RegistryNumber>
<NameOfSubstance UI="D005682">Gadolinium</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D002614" MajorTopicYN="N">Chelating Agents</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003287" MajorTopicYN="N">Contrast Media</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005355" MajorTopicYN="N">Fibrosis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005682" MajorTopicYN="N">Gadolinium</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007674" MajorTopicYN="N">Kidney Diseases</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>21</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year>
<Month>4</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2009</Year>
<Month>6</Month>
<Day>3</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2009</Year>
<Month>6</Month>
<Day>5</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2009</Year>
<Month>8</Month>
<Day>22</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2009</Year>
<Month>8</Month>
<Day>22</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2009</Year>
<Month>11</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">19695369</ArticleId>
<ArticleId IdType="pii">S0003-4509(09)00083-2</ArticleId>
<ArticleId IdType="doi">10.1016/j.pharma.2009.06.002</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/France/explor/LeHavreV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000240 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000240 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/France
   |area=    LeHavreV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:19695369
   |texte=   MRI gadolinium-based contrast agents. Radiologists beware!
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:19695369" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a LeHavreV1

This area was generated with Dilib version V0.6.25.
Data generation: Sat Dec 3 14:37:02 2016. Site generation: Tue Mar 5 08:25:07 2024

	Serveur d'exploration sur la visibilité du Havre
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la visibilité du Havre

MRI gadolinium-based contrast agents. Radiologists beware!

MRI gadolinium-based contrast agents. Radiologists beware!

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki